Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eaton Vance Tax-Managed Buy-Write Opportunities Fund

13.19
+0.09000.69%
Post-market: 13.190.00000.00%16:05 EDT
Volume:117.99K
Turnover:1.56M
Market Cap:1.54B
PE:4.51
High:13.28
Open:13.14
Low:13.14
Close:13.10
Loading ...

Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Dow Jones
·
02 May

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 May

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

GlobeNewswire
·
02 Apr

Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Dow Jones
·
02 Apr

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Apr

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Mar

Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating

TIPRANKS
·
28 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

GlobeNewswire
·
07 Feb

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Feb

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

GlobeNewswire
·
13 Jan

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

GlobeNewswire
·
08 Jan

Press Release: Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Dow Jones
·
01 Jan

Denali Starts Dosing in Phase II Parkinson's Disease Study

Zacks
·
06 Dec 2024

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire
·
07 Nov 2024